0 137

Cited 0 times in

The Prognostic Value of 18F-FDG Uptake in the Supraclavicular Lymph Node (N3c) on PET/CT in Patients With Locally Advanced Breast Cancer With Clinical N3c

DC FieldValueLanguage
dc.contributor.author김동우-
dc.contributor.author김주흥-
dc.contributor.author박형석-
dc.contributor.author윤미진-
dc.contributor.author조호진-
dc.date.accessioned2019-12-18T01:22:04Z-
dc.date.available2019-12-18T01:22:04Z-
dc.date.issued2019-
dc.identifier.issn0363-9762-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/173486-
dc.description.abstractPURPOSE: We investigated the prognostic value of F-FDG uptake in the supraclavicular lymph node (SCLN) on PET/CT in breast cancer patients with clinical ipsilateral SCLN metastasis (cN3c). METHODS: Fifty-five female patients with initial F-FDG PET/CT were treated with curative intent. For semiquantitative analysis, the SUVmax of the primary tumor, axillary lymph node, and SCLN were normalized by the SUVmean of the liver (defined as SUVR-tumor, SUVR-axillary lymph node, and SUVR-SCLN, respectively). Cox proportional hazards models were used to predict disease-free survival (DFS) and overall survival (OS). Differences in DFS and OS were assessed by Kaplan-Meier analysis. RESULTS: Twenty-three patients (41.8%) experienced recurrence, and 13 (23.6%) died during follow-up (median, 70.0 months; range, 6-128 months). In multivariate analysis, SUVR-tumor greater than 3.26 (hazards ratio, 7.26; 95% confidence interval, 1.58-33.31; P = 0.01) and SUVR-SCLN greater than 1.05 (hazards ratio, 8.47; 95% confidence interval, 1.09-65.87; P = 0.04) were prognostic for OS. No clinicopathologic or PET/CT parameters were prognostic for DFS. The patients were divided into 3 groups: group 1 (n = 11, SUVR-tumor ≤3.26 and SUVR-SCLN ≤1.05); group 2 (n = 27, SUVR-tumor >3.26 or SUVR-SCLN >1.05); and group 3 (n = 17, SUVR-tumor >3.26 and SUVR-SCLN >1.05). The 5-year OS rates were 100% in group 1, 85.2% in group 2, and 51.0% in group 3. Group 3 showed worse prognosis than group 1 (P < 0.01) and group 2 (P < 0.01). CONCLUSIONS: In addition to SUVR-tumor, SUVR-SCLN seemed to play an important role in selecting patients with the worst prognosis.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherLippincott-
dc.relation.isPartOfCLINICAL NUCLEAR MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHBiological Transport-
dc.subject.MESHBreast Neoplasms/diagnostic imaging*-
dc.subject.MESHBreast Neoplasms/metabolism*-
dc.subject.MESHBreast Neoplasms/pathology-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHFluorodeoxyglucose F18/metabolism*-
dc.subject.MESHHumans-
dc.subject.MESHLymph Nodes/metabolism*-
dc.subject.MESHLymph Nodes/pathology-
dc.subject.MESHLymphatic Metastasis-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPositron Emission Tomography Computed Tomography*-
dc.subject.MESHRetrospective Studies-
dc.titleThe Prognostic Value of 18F-FDG Uptake in the Supraclavicular Lymph Node (N3c) on PET/CT in Patients With Locally Advanced Breast Cancer With Clinical N3c-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Nuclear Medicine (핵의학교실)-
dc.contributor.googleauthorLee, Suk Hyun-
dc.contributor.googleauthorKim, Sung Hoon-
dc.contributor.googleauthorPark, Hyung Seok-
dc.contributor.googleauthorKim, Joo Heung-
dc.contributor.googleauthorKim, Dongwoo-
dc.contributor.googleauthorCho, Hojin-
dc.contributor.googleauthorYun, Mijin-
dc.identifier.doi10.1097/RLU.0000000000002365-
dc.contributor.localIdA05304-
dc.contributor.localIdA04910-
dc.contributor.localIdA04910-
dc.contributor.localIdA01753-
dc.contributor.localIdA01753-
dc.contributor.localIdA02550-
dc.contributor.localIdA02550-
dc.contributor.localIdA03941-
dc.contributor.localIdA03941-
dc.relation.journalcodeJ00595-
dc.identifier.eissn1536-0229-
dc.identifier.pmid30540598-
dc.identifier.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00003072-201901000-00030&LSLINK=80&D=ovft-
dc.contributor.alternativeNameKim, Dongwoo-
dc.contributor.affiliatedAuthor김동우-
dc.contributor.affiliatedAuthor김주흥-
dc.contributor.affiliatedAuthor김주흥-
dc.contributor.affiliatedAuthor박형석-
dc.contributor.affiliatedAuthor박형석-
dc.contributor.affiliatedAuthor윤미진-
dc.contributor.affiliatedAuthor윤미진-
dc.contributor.affiliatedAuthor조호진-
dc.contributor.affiliatedAuthor조호진-
dc.citation.volume44-
dc.citation.number1-
dc.citation.startPagee6-
dc.citation.endPagee12-
dc.identifier.bibliographicCitationCLINICAL NUCLEAR MEDICINE, Vol.44(1) : e6-e12, 2019-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.